# ğŸ‘ Journal Club

---
## 1. Cancer Immunity
* [Nature Machine Intelligence | Pan-Peptide Meta Learning for T-cell receptorâ€“antigen binding recognition](./File/Article_Pan-Peptide_Meta_Learning_for_T-cell_receptor-antigen_binding_recognition.md) (202305)  

---
## 2. Aptamer
* [Nature | Algorithm for Optimized mRNA Design Improves Stability and Immunogenicity](./File/AlgorithmforOptimizedmRNADesignImprovesStabilityandImmunogenicity.md) (202305)     
* [PNAS | A serum-stable RNA aptamer specific for SARS-CoV-2 neutralizes viral entry](./File/RNA_Aptamerä¸­å’Œæ–°å† ç—…æ¯’å…¥ä¾µçš„RNAé€‚é…ä½“.md) (202110) 
* [Nature Computational Science | Generative aptamer discovery using RaptGen](./File/åˆ†å­ç”Ÿæˆæ·±åº¦å­¦ä¹ RaptGenç”Ÿæˆæ ¸é…¸é€‚é…ä½“.md) (202206)  

---
* [Review | The Progress and Promise of RNA Medicineâ”€ An Arsenal of Targeted Treatments](./File/ç»¼è¿°RNAè¯ç‰©çš„è¿›å±•ä¸å‘å±•å‰æ™¯.md) (202205)
* [Review | Methods and applications of in silico aptamer design and modeling](./File/Review_Methods_and_applications_of_in_silico_aptamer_design_and_modeling.md) (202011)    
* [Review | Computational predictive approaches for interaction and structure of aptamers](./File/ç»¼è¿°é€‚é…ä½“äº’ä½œä»¥åŠç»“æ„çš„è®¡ç®—é¢„æµ‹æ–¹æ³•.md) (202007)    

---
## 3. CADD
### 3.1 åˆ«æ„ç›¸å…³
* [Science | Distinct allosteric mechanisms of first-generationMsbA inhibitors](./File/ScienceMsbAæŠ‘åˆ¶å‰‚çš„è¿œç«¯å˜æ„æŠ‘åˆ¶æœºåˆ¶ç ”ç©¶.md) (202109)
* [JCIM | Research and Evaluation of the Allosteric Protein-Specific Force Field Based on a Pre-Training Deep Learning Model](./File/JCIMé¦–æ¬¾è›‹ç™½å˜æ„åˆ†å­åŠ›åœºä»¥æ•æ‰å˜æ„æ•ˆåº”.md) (202304)

### 3.2 æ–°å† ç—…æ¯’ç›¸å…³
* [Nature | Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor](./File/æ–°å† ç—…æ¯’RBDå’ŒACE2ç»“åˆçš„ç»“æ„åŸºç¡€.md) (202003) 
* [Science | Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir](./File/å°åˆ†å­ç‘å¾·è¥¿éŸ¦æŠ‘åˆ¶RdRpçš„ç»“æ„åŸºç¡€.md) (202006)
* [Nat Chem Biol | Targeted protein S-nitrosylation of ACE2 inhibits SARS-CoV-2 infection](./File/å°åˆ†å­é‡‘åˆšçƒ·ç±»ä¼¼ç‰©é¶å‘ACE2ç¡«äºšç¡åŸºåŒ–ä»è€ŒæŠ‘åˆ¶æ–°å† ç—…æ¯’æ„ŸæŸ“.md) (202305)
* [JMC | Optimization of the Prodrug Moiety of Remdesivir to Improve Lung Exposure/Selectivity and Enhance Anti-SARS-CoV-2 Activity](./File/å°åˆ†å­ç‘å¾·è¥¿éŸ¦ç»“æ„æ”¹é€ æ”¹å–„è‚ºæš´éœ²é‡å’Œé€‰æ‹©æ€§ä»¥å¢å¼ºæŠ—æ–°å† ç—…æ¯’æ•ˆæœ.md) (202209)
* [Viruses | Antiviral Drug Discovery for the Treatment of COVID-19 Infections](./File/è¯ç‰©ç”¨äºæ²»ç–—æ–°å† è‚ºç‚çš„æŠ—ç—…æ¯’è¯ç‰©å‘ç°.md) (202205)
* [JCIM | High-Throughput Virtual Screening and Validation of a SARS-CoV-2 Main Protease Noncovalent Inhibitor](./File/å°åˆ†å­è™šæ‹Ÿç­›é€‰å‘ç°æ–°å† ç—…æ¯’3CLè›‹ç™½éå…±ä»·æŠ‘åˆ¶å‰‚MCULE-5948770040.md) (202111)
* [JMC | Structure-based optimization of ML300-derived, noncovalent inhibitors targeting the severe acute respiratory syndrome coronavirus 3CL protease](./File/å°åˆ†å­æ–°å† ç—…æ¯’3CLéå…±ä»·æŠ‘åˆ¶å‰‚ML300è¡ç”Ÿç‰©çš„ç»“æ„ä¼˜åŒ–.md) (202108)

## 4. AI



## 5. çº³ç±³æµä½“å­¦
* [Chem. Soc. Rev | Nanofluidics, from bulk to interfaces](.File/çº³ç±³æµä½“å­¦ç»¼è¿°_part1.md) (200910)
* [JCP | Nanofluidics at the crossroads](.File/çº³ç±³æµä½“å­¦ç»¼è¿°_part2.md) (202304)